IMMUNOGLOBULIN G1, ANTI-(HUMAN LEUKOCYTE IG-LIKE RECEPTOR A4) (HUMAN MONOCLONAL VIB7734 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL VIB7734 .LAMBDA.-CHAIN, DIMER
Dermatomyositis
Amgenmonoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Dermatomyositis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Northwestern University | Phase 2 | B |
Nivolumab National Cancer Institute (NCI) | Phase 1 | CC |
Ipilimumab National Cancer Institute (NCI) | Phase 1 | CC |
Bms-907351 National Cancer Institute (NCI) | Phase 1 | CC |
Kyv-101 Kyverna Therapeutics | D |
Same molecule, other indications
IMMUNOGLOBULIN G1, ANTI-(HUMAN LEUKOCYTE IG-LIKE RECEPTOR A4) (HUMAN MONOCLONAL VIB7734 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL VIB7734 .LAMBDA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →